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p53th non-toxic doses of zinc in association to the ionophore compound pyrrolidine
dithiocarbamate (PDTC) inhibits p53−/− pancreatic cancer cell growth much more efﬁciently than
gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer. Both the metal chelator N,
N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine and the radical scavenger N-acetyl-L-cysteine are able to
recover cell growth inhibition by Zn/PDTC, demonstrating that this effect depends on the increased levels of
intracellular zinc and of reactive oxygen species (ROS). Zn/PDTC treatment induces a strong apoptotic cell
death that is associated to ROS-dependent nuclear translocation of the mitochondrial factor AIF, but not to
the regulation of apoptotic genes and caspase activation. Primary ﬁbroblasts are more resistant than
pancreatic cancer cells to Zn/PDTC treatment and exhibit a lower basal and Zn/PDTC-induced enhancement
of intracellular zinc. We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome
inhibitor MG132 further increases ﬁbroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation
plays an important role in ﬁbroblast resistance to Zn/PDTC.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic cancer is characterized by high frequency mutations in
TP53, K-RAS, P16, and DPC4 genes [1]. Despite advances in the
understanding of the molecular biology, prognosis of this cancer
remains dismal with a 5-year survival of less than 5% [2] and the gold
standard chemotherapy with gemcitabine is largely ineffective [3].
Zinc is an important modulator of various cellular activities with
both catalytic and structural roles [4]. It is the cofactor of over 300
enzymes and is involved in the stabilization of the three-dimensional
structure of many proteins, including more than 100 transcription
factors containing zinc ﬁnger domains [5]. Owing to these critical
roles, the cellular homeostasis of zinc ions is strictly controlled at
different levels by cell membrane zinc transporters [6], metallothio-
nein sequestration [7], and storing in intracellular compartments
called “zincosomes” [8]. Although zinc is an essential element, its
excess induces apoptosis in different cell lines involving mitochon-
drial injury and oxidative stress production [9,10].
Growing evidence indicates that cancer cells exhibit an intrinsic
oxidative stress higher than normal cells [11,12]. Thus, exposure to
further ROS insults is likely to cause more injury in cancer than in39 045 8027170.
i).
l rights reserved.normal cells because of a more rapid exhaustion of the antioxidant
defences [11]. In line with this observation, it has been found that free
radical production is one of the means by which many anticancer
agents and ionizing radiation exert their killing effect [12].
Here, we report that zinc-mediated ROS increase, obtained by
treating cells with zinc in association to the ionophore pyrrolidine
dithiocarbamate (PDTC), is a strong inhibitor of pancreatic cancer cell
growth, whereas it is much less efﬁcient on normal primary
ﬁbroblasts. Zn/PDTC has a higher activity than gemcitabine and
induces caspase-independent apoptosis that is associated to the
nuclear translocation of the mitochondrial apoptosis inducing factor
(AIF). Furthermore, our data indicate that the resistance of normal
primary ﬁbroblasts to Zn/PDTC treatment most likely depends on i) a
lower basal level and Zn/PDTC-mediated increase of intracellular zinc
compared to pancreatic cancer cells and ii) p53 degradation by Zn/
PDTC-mediated proteasome activation.
2. Materials and methods
2.1. Chemicals
Pyrrolidine dithiocarbamate (PDTC), N-acetyl-L-cysteine (NAC),
zinc sulfate (Sigma) and gemcitabine (GEM; Gemzar, Lilly) were
freshly prepared in sterile water. N,N,N′,N′-tetrakis(2-pyridylmethyl)
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stored at −80 °C until use. The broad spectrum caspase inhibitor Z-
VAD-FMK and the proteasome inhibitor MG132 (Biomol) were
prepared in DMSO and stored at −80 °C until use.
2.2. Cell culture
Four human pancreatic adenocarcinoma cell lines were studied:
PaCa44, T3M4, Panc1, and CFPAC1 [see [1] for genetic characterization
and primary tissue source]. All cell lines were grown in RPMI 1640
supplemented with 20 mM glutamine, 10% FBS and 50 μg/ml
gentamicin sulfate (BioWhittaker) and were incubated at 37 °C with
5% CO2. Primary ﬁbroblasts were grown in DMEM supplemented with
20 mM glutamine, 10% FBS and 50 μg/ml gentamicin sulfate and were
incubated at 37 °C with 5% CO2.
2.3. Cell proliferation assay
Cells were plated in 96-well plates (4×103 cells/well) and 24 h later
were treated with the appropriate compounds (see ﬁgure legends) and
further incubated for 6 or 24 h; then cells were stained with crystal
violet (Sigma). The dye was solubilised in PBS containing 1% SDS and
measured photometrically (A595 nm) to determine cell viability. At the
concentrations used in this work, ZnSO4 remained soluble in 10% FBS
containingmedia, whichwere the same as those used for growing cells.
2.4. Apoptosis
The percentage of apoptotic cells was evaluated by staining 2×105
cells with annexin V-FITC (Bender Med System) and 5 mg/ml
propidium iodide in binding buffer [10 mM HEPES/NaOH (pH 7.4),
140 mM NaOH, and 2.5 mM CaCl2] for 10 min at room temperature in
the dark. The samples were analyzed by ﬂow cytometry (FACScalibur,
Becton-Dickinson) to determine the percentage of cells displaying
annexin V+/propidium iodide− (early apoptosis) or annexin V+/
propidium iodide+ staining (late apoptosis).
Caspase 3 and caspase 8 activities were assayed by cleavage of the
ﬂuorogenic substrates Ac-DEVD-AMC and Ac-IETD-AMC (Biomol),
respectively. After the indicated treatments, cells were washed twice
with ice-cold PBS and lysed in caspase buffer (100mMHEPES, 200mM
NaCl, 1 mM EDTA, 20 mM CHAPS, 10% sucrose). Lysates were prepared
by repeated freeze-thawing, centrifuged at 14,000 ×g for 10 min and
the supernatant fraction saved for analysis. 100 μg of total protein
extractwere incubatedwith 10 μg of theﬂuorogenic peptide substrates
in a total volumeof 800 μl. After a 10min (caspase 3) or 20min (caspase
8) incubation at 30 °C, the release of 7-amino-4-methylcoumarin was
determined ﬂuorometrically (excitation wavelength of 380 nm; emis-
sion wavelength of 460 nm). Optimal amounts of cell lysate and
duration of assay were determined in preliminary experiments.
2.5. Analysis of the intracellular zinc level
Cells (2×105) were stainedwith 2 μMFluoZin-3 (Molecular Probes)
at 37 °C for 30 min, washed in probe-free medium to remove any dye
that is nonspeciﬁcally associated and further incubated for 10 min at
37 °C to allow complete intracellular de-esteriﬁcation of the probe.
Afterwards, cells were washed twice in PBS and analyzed by ﬂow
cytometry (Ex/Em 494/516 nm).
2.6. Analysis of mitochondrial membrane potential (ΔΨm)
Cells (2×105) were stained with 40 nM 3,3-dihexyloxacarbocya-
nine (Molecular Probes) at 37 °C for 20 min and washed twice in PBS.
The percentage of cells exhibiting a decreased level of 3,3-dihexylox-
acarbocyanine uptake, which reﬂects loss of ΔΨm,was determined by
ﬂow cytometry.2.7. RNA extraction, RT-PCR, and image analysis
Total RNA was extracted from 5×106 cells using TRIzol Reagent
(Invitrogen) and 1 μg of RNAwas reverse transcribed using First Strand
cDNA Synthesis for RT-PCR (Invitrogen). For each sample, one tenth of
the cDNA was used as a template for PCR ampliﬁcation using the
following primers and cycling conditions: β-actinFor 5′-ACCAACTGG-
GACGACATGGAGAA-3′ and β-actinRev 5′-GTGGTGGTGAAGCTG-
TAGCC-3′, 25 cycles of 94 °C for 60 s, 55 °C for 60 s and 72 °C for
60s; Bcl-xLFor/Bcl-xSFor 5′-CGGGCATTCAGTGACCTGAC-3′ and Bcl-
xLRev/Bcl-xSRev 5′-TCAGGAACCAGCGGTTGAAG-3′, 35 cycles of 94 °C
for 30 s, 50 °C for 30 s and 72 °C for 30 s; Bcl-wFor 5′-AAGCTGAG-
GCAGAAGGGTTA-3′ and Bcl-wRev 5′-CCCAAAGACAAAGAAGGCTA-3′,
28 cycles of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s; Bcl-2For 5′-
TGCACCTGACGCCCTTCAC-3′ and Bcl-2Rev 5′-AGACAGCCAGGA-
GAAATCAAACAG-3′, BaxFor 5′-ACCAAGAAGCTGAGCGAGTGTC-3′ and
BaxRev 5′-ACAAAGATGGTCACGGTCTGCC-3′, BakFor 5′-TGAAA-
AATGGCTTCGGGGCAAGGC-3′ and BakRev 5′-TCATGATTTGAA-
GAATCTTCGTACC-3′, NoxaFor 5′-TGTCCGAGGTGCTCCAGTTG-3′ and
NoxaRev 5′-TGCACCTTCACATTCCTCTC-3′, p53For 5′-CTGTGACTTG-
CACGTACTCC-3′ and p53Rev 5′-CCATGCAGGAACTGTTACAC-3′,
30 cycles of 94 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s. PCR
products were separated by electrophoresis through ethidium
bromide-stained 2.0% agarose gel and visualized by ultraviolet light.
2.8. Measurement of reactive oxygen species (ROS) production
The non-ﬂuorescent 2′,7′-dichloroﬂuorescin diacetate (DCF) probe,
which becomes highly ﬂuorescent on reaction with ROS, was used to
evaluate cellular ROS production. Brieﬂy, 2×105 cells were incubated
with 10 μMDCF (Sigma) at 37 °C for 15 min and then analyzed by ﬂow
cytometry.
2.9. Immunocytochemistry
Cells (3–5×105) were grown on coverslips and treated as indicated.
Cells were washed twice in PBS, then ﬁxed with 4% paraformaldehyde
in PBS at room temperature for 30 min and permeabilised with
acetone at −20 °C for 3 min. Coverslips were washed twice in PBS,
incubated for 10 min with blocking solution (5% BSA in PBS) and
probed with rabbit anti-human AIF antibody, (1:100 in blocking
solution; Chemicon International) at room temperature for 1 h. Cells
were subsequently washed three times in PBS and incubated with
Alexa Fluor 488 anti-rabbit IgG antibody (1:200 in blocking solution;
Invitrogen) in the dark at room temperature for 1 h. To assess nuclear
morphology, cells were incubated with 4′,6-diamidino-2-phenylin-
dole (DAPI) (1 μg/ml, Invitrogen) in the dark at room temperature for
8min. Finally, cells werewashed three times in PBS andmountedwith
100% glycerol. Fluorescence was visualized using excitation/emission
wavelengths of 488/520 nm (green) and 350/460 nm (blue) for AIF
and DAPI, respectively. Cells were examined using a Canon ﬂuores-
cence microscope with a 40× magniﬁcation.
2.10. Immunoblot analysis
Cells were collected, washed in phosphate-buffered saline, and
resuspended in 20 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM NaF, 1 mM Na3VO4, and 1×protease inhibitor cocktail
(Roche). After three freeze/thaw cycles, the lysate was centrifuged at
14,000 ×g for 10min at 4 °C and the supernatant was used forWestern
blot analysis. Protein concentration was measured with the Bradford
protein assay reagent (Pierce) using bovine serum albumin as a
standard. Fifty micrograms of protein extracts were electrophoresed
through a 12% SDS-polyacrylamide gel and electro-blotted onto PVDF
membranes (Millipore, Italy). Membranes were then incubated over-
night at 4 °C with blocking solution [5% low-fat milk in TBST (100 mM
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temperature with the primary antibody anti-human phospho-p53
(Ser15) (1:1500 in blocking solution, Cell Signaling Technology) or
anti-human p53 (1:500 in blocking solution, Santa Cruz Biotechnol-
ogy). Horseradish peroxidase conjugated anti-mouse IgG (1:1000 in
blocking solution, Upstate Biotechnology) was used to detect speciﬁc
proteins. Immunodetection was carried out using the ECL chemilu-
minescent substrates (Amersham Pharmacia Biotech) and recorded
using a HyperﬁlmECL (Amersham Pharmacia Biotech).
2.11. Statistical analysis
ANOVA (post hoc Bonferroni) analysis and graphical presentations
were performed by GraphPad Prism version 5. p values less than 0.05,
0.01 or 0.001 were indicated as ⁎, ⁎⁎ or ⁎⁎⁎, respectively.Fig. 1. Zn/PDTC treatment increases intracellular zinc level and inhibits pancreatic adeno
adenocarcinoma cell lines (PaCa44, CFPAC1, Panc1, T3M4) and normal primary ﬁbroblasts w
using the crystal violet colorimetric assay as described in Materials and methods. Values are t
versus pancreatic cell lines). (b) PaCa44 cells and normal primary ﬁbroblasts were treated fo
(▴). The FlouZin3 ﬂuorescence intensity, corresponding to the intracellular zinc level, wasme
Values are the means of three independent experiments. ⁎⁎⁎pb0.001 (PDTC or Zn/PDTC vers
cancer cell lines (PaCa44, CFPAC1, Panc1, T3M4) and normal primary ﬁbroblasts were treat
proliferation was determined using the crystal violet colorimetric assay. Values are the mean
versus ZnSO4 or PDTC or GEM in all cells; Zn/PDTC in tumoural cells versus Zn/PDTC in ﬁbr3. Results
3.1. Zn/PDTC treatment strongly inhibits pancreatic adenocarcinoma
cell growth
The antiproliferative effect of zinc was analyzed by treating
PaCa44, CFPAC1, Panc1, and T3M4 pancreatic adenocarcinoma cell
lines and normal primary ﬁbroblasts with increasing doses of zinc
ions. Fig. 1a shows that zinc determined a dose-dependent growth
inhibition in all cell lines. This effect was considerably less intense in
ﬁbroblasts.
To test whether PDTC may enhance the cytotoxic effect of zinc, we
ﬁrst measured the zinc uptake by cells treated with 250 μM PDTC in
the absence or presence of a non-toxic dose of zinc (10 μM, see Fig. 1a).
Fig. 1b shows that the basal level of the intracellular zinc was 8-foldcarcinoma cell growth more efﬁciently than normal ﬁbroblasts. (a) Four pancreatic
ere treated with increasing doses of ZnSO4 for 24 h. Cell proliferation was determined
he means of triplicate wells from three independent experiments. ⁎⁎pb0.01 (ﬁbroblasts
r the indicated time points with 10 μM ZnSO4 (■), 250 μM PDTC (◊), or their association
asured by ﬂowcytometry in arbitrary units (a.u.), as described inMaterials andmethods.
us ZnSO4, Zn/PDTC versus PDTC both in PaCa44 cells and ﬁbroblasts) (c) Four pancreatic
ed with 10 μM ZnSO4 and/or 250 μM PDTC, or 2 μM gemcitabine (GEM) for 24 h. Cell
s of triplicate wells from three independent experiments (±SD). ⁎⁎⁎pb0.001 (Zn/PDTC
oblasts).
Fig. 3. Zn/PDTC treatment strongly induces ROS-dependent apoptosis. (a) PaCa44 cells
were treated with 250 µM PDTC and 10 μM ZnSO4 in the absence or presence of 10 µM
TPEN or 20 mM NAC for 6 h. The 2′,7′-dichloroﬂuorescin (DCF) ﬂuorescence intensity,
corresponding to ROS production level, wasmeasured by ﬂowcytometry as described in
Materials and methods. Values are the means of three independent experiments (±SD).
(b) PaCa44 cells were treated for 6 h with 10 μM ZnSO4 and 250 μM PDTC in the absence
or presence of 10 μM TPEN or increasing concentrations of NAC. The FlouZin3
ﬂuorescence intensity, corresponding to the intracellular zinc level, was measured by
ﬂow cytometry in arbitrary units (a.u.), as described in Materials and methods. Values
are the means of three independent experiments (±SD). (c) PaCa44 cells were treated
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zinc uptake of about 12-fold both in ﬁbroblasts and PaCa44 cells. As
expected, also PDTC alone increased the intracellular zinc level, most
likely by transferring into the cells zinc ions present in the culture
medium. Fig. 1c shows that the exposure of cells to 10 μM zinc and
250 μM PDTC resulted in a stronger growth inhibition compared to
PDTC alone. Noteworthy, Zn/PDTC treatment inhibited cell prolifera-
tionmuchmore efﬁciently than gemcitabine (GEM), the gold standard
chemotherapeutic agent for pancreatic cancer, and was much more
efﬁcient on pancreatic tumour cell lines than on normal ﬁbroblasts
(Fig. 1c). All together these data indicate that zinc-based treatment
may be considered a novel efﬁcient strategy to selectively inhibit
pancreatic cancer cell growth.
3.2. The antiproliferative effect of Zn/PDTC is due to ROS-dependent
apoptotic cell death
Fig. 2 shows that cell growth inhibition by Zn/PDTC treatment,
analyzed at 6 h for PaCa44 cells and 24 h for ﬁbroblasts, was recovered
by the metal chelator TPEN or by the free radical scavenger NAC. The
same experiment performed on PaCa44 cells treated for 24 h did not
allow TPEN or NAC to completely recover cell viability inhibited by Zn/
PDTC (Supplementary Fig. 1). On the other hand, ﬁbroblasts were
completely resistant to a 6 h treatment with Zn/PDTC (data not
shown). Fig. 3a reports that Zn/PDTC determined a 5.5-fold ROS
increase and that ROS production was totally abrogated by the
addition of TPEN or NAC. As shown in Fig. 3b, TPEN was able to
completely abrogate the zinc increase determined by Zn/PDTC
treatment of cells, while NAC only partially decreased intracellular
zinc in a dose dependent manner.
Flow cytometric analysis with annexin V-FITC and propidium
iodide staining showed that treatment with Zn/PDTC induced a
massive apoptotic cell death of PaCa44 cells (Fig. 3c), which was not
observed after treatment with PDTC or zinc alone and was totally
prevented by TPEN or by NAC at all concentrations tested, both at 6 h
(see Fig. 3c) and 24 h (data not shown). This result and that shown in
Fig. 3b indicate that NACwas protective even though Zn/PDTCwas still
taken up into the cells. Altogether, our results strongly suggest that the
apoptotic event is dependent on the intracellular zinc increase and on
the consequent ROS production. Consistent with the ﬂow cytometric
analysis, Zn/PDTC induced the release of nucleosomes in the
cytoplasmic fraction of the cells, indicating the occurrence of
apoptotic DNA cleavage (data not shown).Fig. 2. NAC or TPEN recovers cell growth inhibition by Zn/PDTC treatment. PaCa44 cells
and normal primary ﬁbroblasts were treated with 250 μM PDTC and 10 μMZnSO4 in the
absence or presence of 10 μM TPEN and/or 20 mM NAC for 6 h (PaCa44 cells) and 24 h
(ﬁbroblasts). Cell proliferation was determined using the crystal violet colorimetric
assay. Values are the means of triplicate wells from three independent experiments
(±SD). ⁎⁎⁎pb0.001, ⁎⁎pb0.01.
with 250 μM PDTC and/or 10 μM ZnSO4 in the absence or presence of 10 μM TPEN or
increasing concentrations of NAC for 6 h. 2×105 cells were analyzed by ﬂow cytometry
to determine the percentage of cells displaying annexin V+/propidium iodide− (early
apoptosis) or annexin V+/ propidium iodide+ staining (late apoptosis). The values are the
means of three independent experiments (±SD).3.3. Zn/PDTC determines ROS-dependent mitochondrial damage without
activating caspases
It has been demonstrated that the production of ROS can increase
mitochondrial membrane permeability, thus promoting the mitochon-
drion-mediated cell death program [13]. To determine whether
mitochondria were involved in the apoptosis induced by Zn/PDTC, we
measured the percentage of cells presenting a reduced mitochondrial
membrane potential (ΔΨm). In agreement with the apoptotic analyses
(see Fig. 3c), either zinc or PDTC alone did not increase the percentage of
cells with reduced ΔΨm compared with control, whereas the exposure
to Zn/PDTC led to a reduction of ΔΨm in more than 50% of the cells
(Fig. 4a). Moreover, TPEN or NAC addition totally prevented mitochon-
drial damage, demonstrating that this event depends on zinc intracel-
lular increase and ROS production. Fig. 4b shows that zinc and/or PDTC
treatments did not regulate the expression levels of some of the most
Fig. 4. Zn/PDTC treatment determines ROS-dependent mitochondrial damage and nuclear translocation of AIF. (a) PaCa44 cells were treated with 250 μMPDTC and/or 10 μMZnSO4 in
the absence or presence of 10 μMTPENor 20mMNAC for 24h. The percentage of cells exhibiting a reducedΔΨmwas determined byﬂowcytometry using 3,3-dihexyloxacarbocyanine
staining as described in Materials and methods. Values are the means of three independent experiments (±SD). ⁎⁎⁎pb0.001. (b) RT-PCR analysis of the apoptotic and anti-apoptotic
genes has been performed on total RNA obtained from PaCa44 cells treated with 250 μM PDTC and/or 10 μM ZnSO4 for 8 h. Primer sequences and PCR conditions are described in
Materials andmethods. The results shown are representative of three independent experiments. The same resultswere obtainedwith incubation times of 16 and 24 h. (c) PaCa44 cells
were exposed to 250 μMPDTC and 10 μMZnSO4 for the indicated time. Caspase 3 and 8 activities were assessed as described inMaterials andmethods. PaCa44 cells were treated with
250 μMPDTC and 10 μMZnSO4 and/or 100 μMZ-VAD-FMK, a pan caspase inhibitor, for 24 h. Cell proliferationwas determined using the crystal violet colorimetric assay. Values are the
means of triplicatewells from three independent experiments (±SD). (d) PaCa44 cells were treatedwith 250 μMPDTC and/or 10 μMZnSO4 in the absence or presence of 10 μMTPEN or
20 mM NAC for 24 h. AIF immunoreactivity (green) appeared within cell nuclei (labelled blue with DAPI) only in cells exposed to PDTC and zinc ions. The results shown are
representative of three independent experiments.
277M. Donadelli et al. / Biochimica et Biophysica Acta 1793 (2009) 273–280important apoptotic (BAK, BAX, BCL-XS, and NOXA) and anti-apoptotic
(BCL-2, BCL-W, and BCL-XL) genes, which are well known to promote or
inhibit mitochondrial membrane damage, respectively.
Caspase activity assays demonstrated that both caspase 3 and
caspase 8 were not activated following Zn/PDTC treatment and that
the pan caspase inhibitor Z-VAD-FMK was not able to recover cell
death by Zn/PDTC (Fig. 4c).
3.4. Zn/PDTC-induced apoptosis is associated to ROS-dependent nuclear
translocation of AIF
Fig. 4d shows that treatment with Zn/PDTC determined a virtually
complete nuclear translocation of the mitochondrial apoptotic
inducing factor (AIF), which was totally abolished by TPEN or NAC.In contrast, zinc or PDTC alone were not able to promote nuclear
translocation of AIF, according to the lack of apoptosis (Fig. 3c) and
mitochondrial damage (Fig. 4a). These results were conﬁrmed by
Western blot assays using nuclear protein extracts (data not shown).
All these data suggest that zinc-dependent ROS burst is responsible for
translocation of AIF and they strongly support the fundamental role of
zinc-mediated ROS generation in pancreatic cancer apoptotic cell
death induced by Zn/PDTC.
3.5. Zn/PDTC strongly inhibits p53 expression in normal
primary ﬁbroblasts
As shown in Fig. 1c, normal primary ﬁbroblasts were signiﬁcantly
more resistant than cancer cells to Zn/PDTC treatment. However, also
Fig. 6. The proteasome inhibitor MG132 further inhibits ﬁbroblast cell growth by Zn/
PDTC. (a) Western blot analysis of p53 was performed using total protein extracts from
normal ﬁbroblasts treated with 250 μM PDTC plus 10 μM ZnSO4 and/or 100 μM MG132
for 6 h. The result shown is representative of three independent experiments. (b)
Normal primary ﬁbroblasts were treated with 250 μM PDTC plus 10 μM ZnSO4 in the
absence or presence of increasing concentrations of MG132 for 24 h. Cell growth was
not signiﬁcantly altered by treatment with MG132 alone (data not shown). Cell
proliferation was determined using the crystal violet colorimetric assay. Values are the
means of triplicate wells from three independent experiments (±SD). ⁎⁎⁎pb0.001.
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the reduction of cell viability as demonstrated by the complete
recovery of cell proliferation by TPEN or NAC (Fig. 2).
We have previously reported that p53 phosphorylation in Ser15
induced by PDTC can protect cells from oxidative stress via the
activation of the antioxidant gene SESN2 [14,15]. Here, we show that
the association Zn/PDTC neither increased the level of p53-(Ser15)-
phosphorylation induced by PDTC alone, nor regulated the expression
of antioxidant (SESN1, SESN2, and GPX1) and apoptotic (BAX, BAK and
NOXA) p53-target genes (Supplementary Fig. 1). Zn/PDTC, however,
strongly reduced p53 level by Zn- and ROS-dependent mechanisms
(Fig. 5a and Supplementary Fig. 2), without altering TP53 mRNA
expression (Fig. 5b).
3.6. The proteasome inhibitor MG132 further inhibits ﬁbroblast cell
growth by Zn/PDTC
To investigate whether the proteasome was involved in p53
inhibition and in the reduced sensitivity of normal cells to Zn/PDTC
treatment, we treated ﬁbroblasts with the proteasome inhibitor
MG132. Fig. 6 shows that MG132 was able to recover p53 degradation
by Zn/PDTC (Fig. 6a) and that increasing concentrations of MG132 in
the presence of Zn/PDTC determined a dose-dependent growth
reduction compared to Zn/PDTC (Fig. 6b). MG132 alone did not
signiﬁcantly alter cell viability (data not shown). Altogether these data
suggest that p53 degradation is an important event in ﬁbroblast
protection from Zn/PDTC-induced cell death.
4. Discussion
We have recently demonstrated that the ionophore compound
PDTC inhibits growth of p53-negative human pancreatic cancer cell
lines, while it has no effect on primary ﬁbroblasts. We have also
reported that PDTC is able to transport zinc ions present in the
medium into the cells inducing a modest oxidative stress that is
responsible for S-phase cell cycle arrest, but not for apoptotic cell
death [14].Fig. 5. Zn/PDTC treatment inhibits p53 expression in normal primary ﬁbroblasts. (a)
Western blot analysis of p53 and P(Ser15)-p53 was performed using total protein
extracts from normal ﬁbroblasts treated with 250 μM PDTC and 10 μM ZnSO4 in the
absence or presence of 10 μM TPEN and/or 20 mM NAC for 6 h. The same result was
obtained with an incubation time of 16 h. (b) RT-PCR analysis of TP53 mRNA was
performed on total RNA obtained from normal ﬁbroblasts treated with 250 μM PDTC
and/or 10 μM ZnSO4 for 6 h. Primer sequences and PCR conditions are described in
Materials and methods. The results shown are representative of three independent
experiments.We show here that a further increase of intracellular zinc, obtained
by adding a non-toxic concentration of zinc to PDTC, induces on
pancreatic cancer cells a much stronger ROS production (5.5-fold), as
compared to PDTC alone (∼2-fold). This event determines a strong
apoptotic cell death, as suggested by the total recovery of viability
after treatment with the metal chelator TPEN or the radical scavenger
NAC. However, because of zinc binding activity of NAC, although very
weak, we are unable to exclude that at least part of the apoptotic event
depends directly on the intracellular zinc increase and not on the
consequent ROS production. Anyway, the different trend of the two
dose-dependent curves shown in Fig. 3b and c strongly suggests that
the anti-apoptotic effect of NAC is not correlated with its chelating
activity.
We report that the intracellular Zn/ROS increase generates a
reduction of the mitochondrial membrane potential and the nuclear
translocation of AIF, without affecting the expression of apoptotic and
anti-apoptotic genes or caspase 3 and 8 activities. The analysis of the
cell cycle shows that Zn/PDTC does not further induce pancreatic
cancer cell cycle arrest in the S-phase by PDTC alone [14], indicating
that the enhancement of cell growth inhibition by the addition of zinc
to PDTC (Fig. 1c) is not caused by a stronger cytostatic effect
(Supplementary Fig. 3).
In the last few years, it has been demonstrated that zinc ions are
able to induce oxidative stress via quite different molecular mechan-
isms. They can stimulate ROS production by i) interacting with and
inhibiting the mitochondrial complex III thus inducing mitochondrial
respiration impairment [16,17]; ii) inhibiting glutathione reductase
activity [18]; iii) inhibiting the lipoamide dehydrogenase multi-
enzyme complex (LADH), which has a role in the preservation of the
reducing environment of mitochondria [19].
Abnormally high levels of ROS have been demonstrated to trigger
opening of mitochondrial permeability transition pores (mPTPs) and
release into the cytosol of several different molecules that eventually
Fig. 7.Model of Zn/PDTC action. The molecular mechanisms identiﬁed in this study are
shown. See text for further details.
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demonstrated that a modest induction of ROS by PDTC is capable of
inducing p21-mediated cell cycle arrest in pancreatic cancer cells [14].
In the present manuscript, we show that a stronger increase of the
ROS level determined by the association Zn/PDTC leads to a massive
caspase-independent apoptosis associated to AIF release with no
further increase of the cell cycle arrest. It has been demonstrated that
mammalian cells can undergo apoptosis displaying a large-scale DNA
fragmentation, which is uncoupled from caspase activation [20,21]
and is dependent on AIF nuclear translocation [20]. In agreement with
these observations, the apoptosis induced by Zn/PDTC treatment
produces a large-scale DNA fragmentation that is not associated to the
release of cytochrome c (data not shown). Altogether these data
suggest that AIF may be the major effector of Zn/PDTC-induced
apoptosis in pancreatic cancer cells.
Compared to pancreatic cancer cells, normal ﬁbroblasts are less
sensitive to Zn/PDTC treatment. Previously, we have reported that
ﬁbroblasts are totally resistant to the cytotoxic action of PDTC alone.
This protective effect is most likely dependent on the activation of p53,
via Ser 15 phosphorylation, and of p53-dependent antioxidant genes,
which prevent the oxidative stress [14]. Here, we report that Zn/PDTC
is able to inhibit ﬁbroblast cell growth, although at a lower extent than
pancreatic cells, by oxidative stress induction, as demonstrated by the
total abrogation of the cytotoxic effect in the presence of NAC.
Consistent with these results, the amount of Ser15-phosphorylated
p53 remains unchanged following Zn/PDTC treatment as well as the
levels of the antioxidant p53-target genes. Thus, a stronger oxidative
stress determined by Zn/PDTC compared to PDTC alone, is neither able
to activate p53 and its target antioxidant genes nor to totally protect
cells from growth inhibition. However, ﬁbroblasts appear more
resistant than pancreatic adenocarcinoma cells to Zn/PDTC action.
This effect correlates with the lower level of the intracellular zinc
concentration following Zn/PDTC treatment in ﬁbroblasts compared
to pancreatic cancer cells.
Normal p53-wt cells, in contrast to p53-negative pancreatic
adenocarcinoma cells, may activate the p53-mediated mechanisms
of cell cycle arrest and/or apoptosis to counteract ROS induced DNA
damage and its effects, thus further promoting cell growth inhibition.
However, our data on normal ﬁbroblasts demonstrate that Zn/PDTC
treatment strongly reduces the level of p53 in a ROS-dependent
manner, whereas either Ser15-phosphorylated p53 or p53 mRNA
levels remain unchanged. Indeed, p53 inhibition by Zn/PDTC is due to
enhanced degradation by the proteasome, as indicated by the
abrogation of the effect in the presence of the proteasome inhibitor
MG132. In addition, increasing concentrations of MG132 furtherinhibit ﬁbroblast growth by Zn/PDTC, strongly suggesting that p53
degradation has an important role to prevent ROS-induced apoptosis
in ﬁbroblasts. It has recently been shown that besides its activity as a
transcriptional regulator of apoptotic genes, p53 also exerts a direct
pro-apoptotic role at the mitochondria [22]. Transcriptional functions
of p53 require speciﬁc phosphorylations [23], whereas the direct
apoptotic effect does not depend on p53 phosphorylation/acetylation
[24]. Thus, our results suggest that the strong reduction of the p53
level determined by Zn/PDTC treatment of ﬁbroblasts may decrease
the contribution of the direct effect of p53 on apoptosis and protect
cells from the cytotoxic effect of Zn/PDTC. Fig. 7 shows a model of the
molecular mechanisms deduced from our data.
In cancer therapy, strategies are focused to reduce side effects that
generally cause excessive apoptotic cell death in normal tissues. The
aim is to develop small molecules that inhibit p53 to protect normal
tissues from chemo- and radiotherapy [25]. Our demonstration that
Zn/PDTC is able to strongly inhibit p53 expression in normal cells and
is much more efﬁcient than the gold standard gemcitabine in
pancreatic cancer cell growth inhibition makes ROS increase by
intracellular zinc enhancement a possible novel and efﬁcient strategy
for pancreatic cancer treatment.
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